Parsons Capital Management Inc. RI Has $1.61 Million Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Parsons Capital Management Inc. RI lowered its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 12.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 167,149 shares of the company’s stock after selling 23,497 shares during the period. Parsons Capital Management Inc. RI owned about 0.11% of MiMedx Group worth $1,608,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of MDXG. Harbor Capital Advisors Inc. raised its stake in MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after acquiring an additional 770,744 shares in the last quarter. Millennium Management LLC increased its position in MiMedx Group by 339.9% during the 2nd quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock worth $6,164,000 after purchasing an additional 687,267 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in MiMedx Group by 47.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after purchasing an additional 413,443 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after purchasing an additional 215,995 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock valued at $1,806,000 after acquiring an additional 174,797 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Price Performance

MiMedx Group stock opened at $8.71 on Tuesday. The stock’s 50 day moving average price is $9.20 and its two-hundred day moving average price is $7.49. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of 15.84 and a beta of 1.96. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $84.06 million during the quarter, compared to analysts’ expectations of $81.00 million. During the same period last year, the company posted $0.05 earnings per share. On average, equities analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, MiMedx Group presently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.